M

Magle Chemoswed Holding AB
STO:MAGLE

Watchlist Manager
Magle Chemoswed Holding AB
STO:MAGLE
Watchlist
Price: 32.6 SEK -4.12% Market Closed
Market Cap: 599.9m SEK
Have any thoughts about
Magle Chemoswed Holding AB?
Write Note

Magle Chemoswed Holding AB
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Magle Chemoswed Holding AB
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
M
Magle Chemoswed Holding AB
STO:MAGLE
Net Income (Common)
kr12.2m
CAGR 3-Years
89%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Net Income (Common)
kr190m
CAGR 3-Years
-28%
CAGR 5-Years
8%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Net Income (Common)
-kr2B
CAGR 3-Years
-245%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Net Income (Common)
kr257m
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
17%
G
Genovis AB
STO:GENO
Net Income (Common)
kr17.3m
CAGR 3-Years
14%
CAGR 5-Years
30%
CAGR 10-Years
N/A
MedCap AB (publ)
STO:MCAP
Net Income (Common)
kr227.9m
CAGR 3-Years
44%
CAGR 5-Years
48%
CAGR 10-Years
32%
No Stocks Found

Magle Chemoswed Holding AB
Glance View

Market Cap
599.9m SEK
Industry
Life Sciences Tools & Services

Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.

MAGLE Intrinsic Value
83.52 SEK
Undervaluation 61%
Intrinsic Value
Price
M

See Also

What is Magle Chemoswed Holding AB's Net Income (Common)?
Net Income (Common)
12.2m SEK

Based on the financial report for Dec 31, 2023, Magle Chemoswed Holding AB's Net Income (Common) amounts to 12.2m SEK.

What is Magle Chemoswed Holding AB's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
89%

Over the last year, the Net Income (Common) growth was 33%. The average annual Net Income (Common) growth rates for Magle Chemoswed Holding AB have been 89% over the past three years .

Back to Top